Silo Pharma Inc

Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in merging traditional therapeutics with psychedelic research. It seeks to acquire and develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs. The company was founded by Eric Weisblum on July 13, 2010 and is headquartered in Englewood Cliffs, NJ.

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. It seeks to acquire and develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs. The company was founded by Eric Weisblum on July 13, 2010 and is headquartered in Sarasota, FL.

Aion Therapeutic Inc (CSE:AION), Lobe Sciences Ltd (CSE:LOBE) (OTCMKTS: (GTSIF) and Silo Pharma Inc (OTCMKTS:SILO) are presenting at Proactive's next virtual showcase event on February 23. The psychedelic-themed event will be hosted by Proactive's Christine Corrado and kicks off on Tuesday at 1 PM ET.

Aion Therapeutic: Meet the team using artificial intelligence to create a full lineup of psychedelic and cannabis therapies

Silo Pharma Inc (OTCMKTS:SILO) will be presenting with Lobe Sciences Ltd (CSE:LOBE) (OTCMKTS: (GTSIF) at Proactive's next virtual showcase event on February 23. The psychedelic-themed event will be hosted by Proactive's Christine Corrado and kicks off on Tuesday at 1 PM ET.

Silo Pharma: Meet the team bridging the gap between traditional pharmaceuticals and psychedelic therapies

Targeting innovative treatments for multiple sclerosis and other neuroinflammatory pathology Targeting innovative treatments for multiple sclerosis and other neuroinflammatory pathology

Silo Pharma Licenses Novel Peptide-Guided Drug Delivery Approach for the Treatment of MS

Silo Pharma to pursue additional strategic partnerships and intellectual property acquisitions in the psychedelic medicine space

Silo Pharma Announces Private Placement of Equity Definitive Agreement for $4.275 Million in Gross Proceeds

Silo Pharma Inc. is a biopharmaceutical company focused on merging traditional therapeutics with psychedelic research to address underserved medical conditions.Whitefish, Montana--(Newsfile Corp. - February 10, 2021) - CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced the addition of Silo Pharma Inc. (OTCQB: SILO) to its growing cannabis and psychedelics client roster.

Silo Pharma Inc. Engages CFN Enterprises Inc. to Reach Psychedelics Investor Audience

Englewood Cliffs, NJ, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson's, and other rare neurological disorders, announced today it has exercised its option to take an exclusive license for patents owned by the University of Maryland Baltimore for the treatment of Neuroinflammatory Disease.

Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease

Phoenix, Arizona--(Newsfile Corp. - January 20, 2021) - The Stock Day Podcast welcomed Silo Pharma Inc. (OTCQB: SILO) ("the Company"), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson's, and other rare neurological disorders. CEO of the Company, Eric Weisblum, joined Stock Day host Everett Jolly. "Personally, I have over 20 years of experience investing and working in the private and...

Silo Pharma Inc. Discusses The Potential of Merging Traditional Therapeutics with Psychedelic Research On The Stock Day Podcast

NEW JERSEY , Jan. 19, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson's, and other rare neurological disorders, today announced that Founder and CEO Eric Weisblum will participate in the “Investing in Psychedelics Series: Building Value Through IP” virtual conference hosted by The Canadian Securities Exchange (CSE), CFN Media Group (OTCQB: CNFN) and Zuber Lawler on Wednesday, January 20, 2021. The live panel discussion is scheduled to begin at 1 PM EST. and will be followed by a Q&A session.

Silo Pharma to Participate in Virtual Conference on Investing in Psychedelics

Silo Pharma could Utilize Data for Psilocybin Delivery potential to Central Nervous System Silo Pharma could Utilize Data for Psilocybin Delivery potential to Central Nervous System

Silo Pharma Enters into Sponsored Research Agreement for Potential Multiple Sclerosis Treatment Approach with University of Maryland, Baltimore

Englewood Cliffs, NJ, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has entered into an agreement to license technology covered by provisional patent applications filed by Silo Pharma with the United States Patent and Trademark Office in use for patients suffering with cancer. Silo Pharma's patent applications relates to using a novel peptide with Psilocybin as a therapeutic.

Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities

Englewood Cliffs, NJ, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that its Board of Directors has named clinical researcher and professor, Dr. Charles B. Nemeroff, M.D., Ph.D., to its Scientific Advisory Board.

Silo Pharma, Inc. Enhances Scientific Advisory Board with Appointment of Dr. Charles B. Nemeroff of University of Texas at Austin

NEW JERSEY, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that its Board of Directors has named behavioral health expert Dr. Peter Hendricks, Ph.D. to its newly formed Scientific Advisory Board.

Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham

NEW JERSEY , Dec. 04, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has been requested by the OTC Markets Group (“the OTC Markets”) to comment on recent promotional activity.

Silo Pharma Comments on Recent Promotional and Trading Activities at Request of OTC Markets

NEW YORK , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) today announced that its Board of Directors has named scientific research investigator Dr. Joshua Woolley, M.D. / Ph.D. to its newly formed Scientific Advisory Board.  

Silo Pharma, Inc. Expands Scientific Advisory Board with the Appointment of Dr. Joshua Woolley of University of California, San Francisco

Each Provisional Patent Application Relates to Psilocybin

Silo Pharma, Inc. Announces Filing of Three U.S. Provisional Patent Applications

Industry Recognized Expert in Psychedelics and Related Safety Guidelines Industry Recognized Expert in Psychedelics and Related Safety Guidelines

Silo Pharma, Inc. Launches Scientific Advisory Board with Appointment of Dr. Matthew Johnson of John Hopkins University

To Begin Trading on the OTCQB Venture Market Under the Symbol “SILO” Today

News for Silo Pharma Inc Stock (SILO)